These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 35572649)

  • 21. The gut microbiota - A vehicle for the prevention and treatment of hepatocellular carcinoma.
    Beyoğlu D; Idle JR
    Biochem Pharmacol; 2022 Oct; 204():115225. PubMed ID: 35998677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
    Kotsiliti E; Leone V; Schuehle S; Govaere O; Li H; Wolf MJ; Horvatic H; Bierwirth S; Hundertmark J; Inverso D; Zizmare L; Sarusi-Portuguez A; Gupta R; O'Connor T; Giannou AD; Shiri AM; Schlesinger Y; Beccaria MG; Rennert C; Pfister D; Öllinger R; Gadjalova I; Ramadori P; Rahbari M; Rahbari N; Healy ME; Fernández-Vaquero M; Yahoo N; Janzen J; Singh I; Fan C; Liu X; Rau M; Feuchtenberger M; Schwaneck E; Wallace SJ; Cockell S; Wilson-Kanamori J; Ramachandran P; Kho C; Kendall TJ; Leblond AL; Keppler SJ; Bielecki P; Steiger K; Hofmann M; Rippe K; Zitzelsberger H; Weber A; Malek N; Luedde T; Vucur M; Augustin HG; Flavell R; Parnas O; Rad R; Pabst O; Henderson NC; Huber S; Macpherson A; Knolle P; Claassen M; Geier A; Trautwein C; Unger K; Elinav E; Waisman A; Abdullah Z; Haller D; Tacke F; Anstee QM; Heikenwalder M
    J Hepatol; 2023 Aug; 79(2):296-313. PubMed ID: 37224925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut microbiota: A new piece in understanding hepatocarcinogenesis.
    Zhou A; Tang L; Zeng S; Lei Y; Yang S; Tang B
    Cancer Lett; 2020 Apr; 474():15-22. PubMed ID: 31917160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
    Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Aspects of Gut Microbiota in Hepatocellular Carcinoma Management.
    Xu J; Zhan Q; Fan Y; Lo EKK; Zhang F; Yu Y; El-Nezami H; Zeng Z
    Pathogens; 2021 Jun; 10(7):. PubMed ID: 34206200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome.
    Golonka RM; Vijay-Kumar M
    Adv Cancer Res; 2021; 149():171-255. PubMed ID: 33579424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting gut flora to prevent progression of hepatocellular carcinoma.
    Darnaud M; Faivre J; Moniaux N
    J Hepatol; 2013 Feb; 58(2):385-7. PubMed ID: 22940407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis.
    Liakina V; Strainiene S; Stundiene I; Maksimaityte V; Kazenaite E
    World J Hepatol; 2022 Jul; 14(7):1277-1290. PubMed ID: 36158907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
    Chen YH; Wu WK; Wu MS
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut microbiota, fatty liver disease, and hepatocellular carcinoma.
    Chu H; Williams B; Schnabl B
    Liver Res; 2018 Mar; 2(1):43-51. PubMed ID: 30416839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
    Jiang JW; Chen XH; Ren Z; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.
    Ponziani FR; Bhoori S; Castelli C; Putignani L; Rivoltini L; Del Chierico F; Sanguinetti M; Morelli D; Paroni Sterbini F; Petito V; Reddel S; Calvani R; Camisaschi C; Picca A; Tuccitto A; Gasbarrini A; Pompili M; Mazzaferro V
    Hepatology; 2019 Jan; 69(1):107-120. PubMed ID: 29665135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.
    Fang J; Yu CH; Li XJ; Yao JM; Fang ZY; Yoon SH; Yu WY
    Front Cell Infect Microbiol; 2022; 12():997018. PubMed ID: 36425787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunomodulation by probiotics and prebiotics in hepatocellular carcinoma.
    Russo E; Fiorindi C; Giudici F; Amedei A
    World J Hepatol; 2022 Feb; 14(2):372-385. PubMed ID: 35317185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment.
    Bartolini I; Risaliti M; Tucci R; Muiesan P; Ringressi MN; Taddei A; Amedei A
    World J Gastrointest Oncol; 2021 Nov; 13(11):1616-1631. PubMed ID: 34853639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
    Schwabe RF; Greten TF
    J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of gut microbiota in liver disease development and treatment.
    Wang L; Wan YY
    Liver Res; 2019 Mar; 3(1):3-18. PubMed ID: 32461811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors.
    Abenavoli L; Montori M; Svegliati Baroni G; Argenziano ME; Giorgi F; Scarlata GGM; Ponziani F; Scarpellini E
    Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629716
    [No Abstract]   [Full Text] [Related]  

  • 40. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.
    Milosevic I; Vujovic A; Barac A; Djelic M; Korac M; Radovanovic Spurnic A; Gmizic I; Stevanovic O; Djordjevic V; Lekic N; Russo E; Amedei A
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.